Compass pathways stock forecast.

4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.

Compass pathways stock forecast. Things To Know About Compass pathways stock forecast.

Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each, meaning Atai paid around $12 ...Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ...Past 5 Years (per annum) N/A. N/A. N/A. N/A. See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.WebThe upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...Current price today: 6.450 USD (+1.896%) History Forecast Data Market Q&A Comments Buy CRYPTO Select other stock... Current Price 6.450 USD 7 Days Forecast Get It …

(Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ...Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...Web

Company Size. 116 Employees. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in ...

Aug 22, 2023 · COMPASS Pathways-stock; ... Compass Pathways has an average price target of $56.82 with a high of $120.00 and a low of $21.00. ... Some analysts will also offer forecasts for metrics like growth ... The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...16 de ago. de 2023 ... The psychedelics biotech firm is set to receive $125 million selling stocks upfront, with a potential addition of $160 million from ...COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.

The average Atai Life Sciences Nv stock price prediction forecasts a potential upside of 1,490.91% from the current ATAI share price of $1.10. What is ATAI's forecast return on equity (ROE) for 2023-2026? (NASDAQ: ATAI) forecast ROE …

COMPASS Pathways plc (COMPASS) operates as a mental health care company. The company engages in the development of a new model of psilocybin therapy, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support. Its initial focus is on treatment-resistant depression (TRD), a subset of major ...

US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and …According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.Nov 30, 2023 · Overview Financials Statistics Forecast Profile Chart Forecast Analyst Ratings COMPASS Pathways Stock Forecast All Analysts Top Analysts Stock Price Forecast According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. (Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...Compass Pathways. Compass Pathways’ roots go back to 2015, when George Goldsmith and Ekaterina Malievskaia founded a nonprofit organization, the Compass Trust Limited, to support research and ...NasdaqGS:CMPS Earnings and Revenue Growth April 12th 2021. COMPASS Pathways is not owned by hedge funds. Our data shows that ATAI Life Sciences AG is the largest shareholder with 22% of shares ...

COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.WebCMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings results on November 2nd, 2023. The reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted earnings per share).Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Some... Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst...Jul 5, 2023 · (Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ... Compass IPO'd in September 2020, raising $147m at $17 per share, so the stock is only trading at a 35%-40% discount to its listing price, which is not too bad based on current biotech bear market ...Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a …

How to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.On average, Wall Street analysts predict. that Compass Pathways's share price could reach $57.25 by Aug 22, 2024. The average Compass Pathways stock price prediction forecasts a potential upside of 857.36% from the current CMPS share price of $5.98.

13 de mar. de 2023 ... Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their 'Buy' rating and US$60 price target for COMPASS Pathways after the ...The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and …May 11, 2023 · In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ... COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the …10 stocks we like better than COMPASS Pathways When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ...Dec 1, 2023 · See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 69.32%. Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...Shares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …

The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...

Biotechnology firm COMPASS Pathways (CMPS) Wednesday announced a private placement of 16.08M American Depositary Shares and warrants to purchase up to 16.08M ADSs at a price of $7.78...

On Nov 02, 2023, Compass Pathways ( NASDAQ: CMPS) reported Q3 2023 earnings per share (EPS) of -$0.67, up 55.81% year over year. Total Compass Pathways earnings for the quarter were -$33.39 million. In the same quarter last year, Compass Pathways 's earnings per share (EPS) was -$0.43. If you're new to stock investing, here's how to buy …Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.WebThe COMPASS Pathways plc stock forecast for tomorrow is $ 5.02, which would represent a -4.68% loss compared to the current price. In the next week, the price of CMPS is expected to decrease by -2.62% and hit $ 5.13. As far as the long-term COMPASS Pathways plc stock forecast is concerned, here’s what our predictions are currently suggesting. Mar 2, 2022 · COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ... Current price today: 6.450 USD (+1.896%) History Forecast Data Market Q&A Comments Buy CRYPTO Select other stock... Current Price 6.450 USD 7 Days Forecast Get It …Compass, Inc. (NYSE:COMP) announced its quarterly earnings data on Monday, November, 6th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.35 billion.WebCompass Pathways (NASDAQ: CMPS) is owned by 35.95% institutional shareholders, 57.27% Compass Pathways insiders, and 6.79% retail investors. Ekaterina Malievskaia is the largest individual Compass Pathways shareholder, owning 12.82M shares representing 20.71% of the company. Ekaterina Malievskaia's Compass Pathways shares are …3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...

Here are some of the best psychedelic sector stocks generating a buzz among investors: — Atai Life Sciences NV (ticker: ATAI) — GH Research PLC ( GHRS) — Compass Pathways PLC ( CMPS ...Compass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ...Compass, Inc. (NYSE:COMP) announced its quarterly earnings data on Monday, November, 6th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.35 billion.WebInstagram:https://instagram. gold information kitbarron's magazine this weekbest mortgage lenders for rental propertyspecial quarters ... targets for tomorrow -CMPS Compass Pathways Plc ADR stock price movement predictions for tomorrow,weekly,monthly -NASDAQ Stock Exchange munafasutra.com.When a company is developing a novel therapy, sometimes good news takes an unusual form. For Compass Pathways, ( CMPS -8.84%) whose COMP360 program aims to address treatment-resistant depression ... mackenzie scott grantnowrx alto pharmacy Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Dec 1, 2023 · COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. best investment firms for retirement Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ... LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role …